Singapore: VolitionRx, a life sciences company focused on developing blood-based diagnostic tests, filed two new patent applications.

While the first patent application is an extension of the nucleosomics technology that is used for the detection of histone modifications in nucleosomes, the second patent covers the use of Volition's nucleosomics technology in personalized medicine as a predictor of the efficacy of cancer treatment.

VolitionRx already holds patent applications worldwide for a number of methods of detecting nucleosomes and nucleosome structures; both in-licensed and self-authored.

"The use of Nucleosomics in the expanding field of personalized cancer medicine is a new early stage development for us but represents an exciting prospect with the potential for real patient benefit," said Mr Jake Micallef, chief scientific officer of VolitionRx.

"These two patents complement our existing Nucleosomics IP, providing us with greater intellectual property protection for our NuQ products", said Mr Cameron Reynolds, CEO, VolitionRx. "While we work towards applying for regulatory approval for our clinical products in both Europe and the US, we continue to carry out research and development in our Belgian laboratory, expanding our intellectual property base and our understanding of the possibilities, both in diagnostics and therapy monitoring - for our Nucleosomics technology."